MANNKIND CORP (MNKD) Fundamental Analysis & Valuation

NASDAQ:MNKD • US56400P7069

2.725 USD
-0.09 (-3.37%)
Last: Mar 13, 2026, 12:29 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This MNKD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Taking everything into account, MNKD scores 5 out of 10 in our fundamental rating. MNKD was compared to 519 industry peers in the Biotechnology industry. While MNKD is still in line with the averages on profitability rating, there are concerns on its financial health. MNKD is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

6

1. MNKD Profitability Analysis

1.1 Basic Checks

  • In the past year MNKD was profitable.
  • In the past year MNKD had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: MNKD reported negative net income in multiple years.
  • In multiple years MNKD reported negative operating cash flow during the last 5 years.
MNKD Yearly Net Income VS EBIT VS OCF VS FCFMNKD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 0.85%, MNKD belongs to the top of the industry, outperforming 88.05% of the companies in the same industry.
  • MNKD has a Return On Invested Capital of 7.96%. This is amongst the best in the industry. MNKD outperforms 92.68% of its industry peers.
  • MNKD had an Average Return On Invested Capital over the past 3 years of 10.85%. This is significantly below the industry average of 19.44%.
Industry RankSector Rank
ROA 0.85%
ROE N/A
ROIC 7.96%
ROA(3y)1.74%
ROA(5y)-9.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.85%
ROIC(5y)N/A
MNKD Yearly ROA, ROE, ROICMNKD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100 -100 -150

1.3 Margins

  • MNKD has a Profit Margin of 1.92%. This is amongst the best in the industry. MNKD outperforms 88.25% of its industry peers.
  • Looking at the Operating Margin, with a value of 16.59%, MNKD belongs to the top of the industry, outperforming 93.06% of the companies in the same industry.
  • Looking at the Gross Margin, with a value of 77.80%, MNKD belongs to the top of the industry, outperforming 84.20% of the companies in the same industry.
  • In the last couple of years the Gross Margin of MNKD has grown nicely.
Industry RankSector Rank
OM 16.59%
PM (TTM) 1.92%
GM 77.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.37%
GM growth 5Y4.31%
MNKD Yearly Profit, Operating, Gross MarginsMNKD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. MNKD Health Analysis

2.1 Basic Checks

  • MNKD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • MNKD has more shares outstanding than it did 1 year ago.
  • MNKD has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for MNKD is higher compared to a year ago.
MNKD Yearly Shares OutstandingMNKD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
MNKD Yearly Total Debt VS Total AssetsMNKD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of -4.17, we must say that MNKD is in the distress zone and has some risk of bankruptcy.
  • MNKD has a Altman-Z score of -4.17. This is comparable to the rest of the industry: MNKD outperforms 40.27% of its industry peers.
  • The Debt to FCF ratio of MNKD is 44.51, which is on the high side as it means it would take MNKD, 44.51 years of fcf income to pay off all of its debts.
  • MNKD's Debt to FCF ratio of 44.51 is amongst the best of the industry. MNKD outperforms 89.98% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 44.51
Altman-Z -4.17
ROIC/WACC0.98
WACC8.15%
MNKD Yearly LT Debt VS Equity VS FCFMNKD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • MNKD has a Current Ratio of 1.70. This is a normal value and indicates that MNKD is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of MNKD (1.70) is worse than 79.38% of its industry peers.
  • MNKD has a Quick Ratio of 1.50. This is a normal value and indicates that MNKD is financially healthy and should not expect problems in meeting its short term obligations.
  • MNKD has a worse Quick ratio (1.50) than 80.92% of its industry peers.
Industry RankSector Rank
Current Ratio 1.7
Quick Ratio 1.5
MNKD Yearly Current Assets VS Current LiabilitesMNKD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. MNKD Growth Analysis

3.1 Past

  • MNKD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -28.75%.
  • Looking at the last year, MNKD shows a very strong growth in Revenue. The Revenue has grown by 22.23%.
  • Measured over the past years, MNKD shows a very strong growth in Revenue. The Revenue has been growing by 39.91% on average per year.
EPS 1Y (TTM)-28.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-266.67%
Revenue 1Y (TTM)22.23%
Revenue growth 3Y51.78%
Revenue growth 5Y39.91%
Sales Q2Q%45.82%

3.2 Future

  • Based on estimates for the next years, MNKD will show a very strong growth in Earnings Per Share. The EPS will grow by 52.44% on average per year.
  • The Revenue is expected to grow by 17.70% on average over the next years. This is quite good.
EPS Next Y-6.55%
EPS Next 2Y91.27%
EPS Next 3Y65.59%
EPS Next 5Y52.44%
Revenue Next Year34.43%
Revenue Next 2Y25.13%
Revenue Next 3Y18.13%
Revenue Next 5Y17.7%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
MNKD Yearly Revenue VS EstimatesMNKD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
MNKD Yearly EPS VS EstimatesMNKD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 0.5 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

5

4. MNKD Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 45.42, MNKD can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, MNKD is valued cheaply inside the industry as 90.17% of the companies are valued more expensively.
  • MNKD's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 25.71.
  • With a Price/Forward Earnings ratio of 51.16, MNKD can be considered very expensive at the moment.
  • Based on the Price/Forward Earnings ratio, MNKD is valued cheaply inside the industry as 90.37% of the companies are valued more expensively.
  • MNKD is valuated expensively when we compare the Price/Forward Earnings ratio to 23.82, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 45.42
Fwd PE 51.16
MNKD Price Earnings VS Forward Price EarningsMNKD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, MNKD is valued cheaply inside the industry as 94.03% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, MNKD is valued cheaper than 92.87% of the companies in the same industry.
Industry RankSector Rank
P/FCF 61.33
EV/EBITDA 16.73
MNKD Per share dataMNKD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • The decent profitability rating of MNKD may justify a higher PE ratio.
  • A more expensive valuation may be justified as MNKD's earnings are expected to grow with 65.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y91.27%
EPS Next 3Y65.59%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MNKD Dividend Analysis

5.1 Amount

  • MNKD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MNKD Fundamentals: All Metrics, Ratios and Statistics

MANNKIND CORP

NASDAQ:MNKD (3/13/2026, 12:29:52 PM)

2.725

-0.09 (-3.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners58.06%
Inst Owner Change3.51%
Ins Owners1.57%
Ins Owner Change2.26%
Market Cap839.57M
Revenue(TTM)348.97M
Net Income(TTM)6.70M
Analysts85.33
Price Target9.8 (259.63%)
Short Float %8.8%
Short Ratio5.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-116.48%
Min EPS beat(2)-439.47%
Max EPS beat(2)206.52%
EPS beat(4)1
Avg EPS beat(4)-85.96%
Min EPS beat(4)-439.47%
Max EPS beat(4)206.52%
EPS beat(8)2
Avg EPS beat(8)-74.12%
EPS beat(12)5
Avg EPS beat(12)-38.6%
EPS beat(16)6
Avg EPS beat(16)-28.6%
Revenue beat(2)2
Avg Revenue beat(2)6.39%
Min Revenue beat(2)0.33%
Max Revenue beat(2)12.45%
Revenue beat(4)3
Avg Revenue beat(4)2.28%
Min Revenue beat(4)-4.55%
Max Revenue beat(4)12.45%
Revenue beat(8)6
Avg Revenue beat(8)2.33%
Revenue beat(12)9
Avg Revenue beat(12)3.51%
Revenue beat(16)12
Avg Revenue beat(16)6.12%
PT rev (1m)0%
PT rev (3m)6.13%
EPS NQ rev (1m)-33.3%
EPS NQ rev (3m)0%
EPS NY rev (1m)-38.97%
EPS NY rev (3m)-51.42%
Revenue NQ rev (1m)7.18%
Revenue NQ rev (3m)9.23%
Revenue NY rev (1m)7.09%
Revenue NY rev (3m)9.77%
Valuation
Industry RankSector Rank
PE 45.42
Fwd PE 51.16
P/S 2.41
P/FCF 61.33
P/OCF 45.99
P/B N/A
P/tB N/A
EV/EBITDA 16.73
EPS(TTM)0.06
EY2.2%
EPS(NY)0.05
Fwd EY1.95%
FCF(TTM)0.04
FCFY1.63%
OCF(TTM)0.06
OCFY2.17%
SpS1.13
BVpS-0.17
TBVpS-1.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.85%
ROE N/A
ROCE 9.32%
ROIC 7.96%
ROICexc 10.76%
ROICexgc 55.79%
OM 16.59%
PM (TTM) 1.92%
GM 77.8%
FCFM 3.92%
ROA(3y)1.74%
ROA(5y)-9.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.85%
ROIC(5y)N/A
ROICexc(3y)28.62%
ROICexc(5y)N/A
ROICexgc(3y)44.91%
ROICexgc(5y)N/A
ROCE(3y)12.18%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.37%
GM growth 5Y4.31%
F-Score5
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 44.51
Debt/EBITDA 8.33
Cap/Depr 37.17%
Cap/Sales 1.31%
Interest Coverage 3.93
Cash Conversion 26.02%
Profit Quality 204.41%
Current Ratio 1.7
Quick Ratio 1.5
Altman-Z -4.17
F-Score5
WACC8.15%
ROIC/WACC0.98
Cap/Depr(3y)368.18%
Cap/Depr(5y)300.07%
Cap/Sales(3y)8.68%
Cap/Sales(5y)9.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-266.67%
EPS Next Y-6.55%
EPS Next 2Y91.27%
EPS Next 3Y65.59%
EPS Next 5Y52.44%
Revenue 1Y (TTM)22.23%
Revenue growth 3Y51.78%
Revenue growth 5Y39.91%
Sales Q2Q%45.82%
Revenue Next Year34.43%
Revenue Next 2Y25.13%
Revenue Next 3Y18.13%
Revenue Next 5Y17.7%
EBIT growth 1Y-18.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-58.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.06%
OCF growth 3YN/A
OCF growth 5YN/A

MANNKIND CORP / MNKD FAQ

What is the fundamental rating for MNKD stock?

ChartMill assigns a fundamental rating of 5 / 10 to MNKD.


Can you provide the valuation status for MANNKIND CORP?

ChartMill assigns a valuation rating of 5 / 10 to MANNKIND CORP (MNKD). This can be considered as Fairly Valued.


Can you provide the profitability details for MANNKIND CORP?

MANNKIND CORP (MNKD) has a profitability rating of 6 / 10.


What are the PE and PB ratios of MANNKIND CORP (MNKD) stock?

The Price/Earnings (PE) ratio for MANNKIND CORP (MNKD) is 45.42 and the Price/Book (PB) ratio is -16.46.